Arming antitumor T cells by Bashyam, Hema
IN THIS ISSUE
696  JEM Vol. 204, No. 4, 2007
The immune system can only prevent cancer if it 
recognizes and destroys precancerous cells. Antigenic 
targets of such an early immune response, however, 
have been elusive. Spisek et al. (page  831) now 
find that an embryonic stem cell marker is a bull’s eye 
for immune cells in patients who have precancerous 
lesions but never develop multiple myeloma.
Multiple myeloma is an incurable cancer that 
occurs throughout the bone marrow. It is caused 
by the uncontrolled proliferation of antibody-
producing B cells, which replace normal immune 
cells as well as red blood cells and platelets. In 
some patients, this malignant cancer is preceded 
by a benign condition known as multiple gammo-
pathy of undetermined significance (MGUS). Dur-
ing this stage, the abnormal B cells do not form 
tumors, and the patients remain healthy. Although 
MGUS occurs in  3% of the population over 50 
years of age, only a third of those with MGUS will 
eventually develop myeloma.
This selective disease protection, the team now 
shows, correlates with the presence of immune re-
sponses against the embryonic transcription factor 
SOX2. SOX2 is normally switched off after 
embryonic stem cells differentiate, but, in both 
MGUS and myeloma 
patients, it is reactivated 
in bone marrow cells that 
are potential tumor pro-
genitors. MGUS patients 
had anti-SOX2 antibodies 
and T cells, but the my-
eloma patients did not. In 
a two-year observational 
study, patients with early 
tumors who had anti-
SOX2 T cells remained 
cancer-free. Those that 
lacked these T cells, however, developed mul-
tiple myeloma.
These findings suggest that an immune response 
against the SOX2-expressing bone marrow cells may 
prevent malignancy. The group is now trying to 
determine whether myeloma patients never mount 
an immune response to SOX2 or simply lose it over 
time. The group’s in vitro evidence suggests that 
anti-SOX2 T cells prevent tumor formation. But 
myeloma patients would have to be vaccinated 
against SOX2 to confirm that these T cells have 
antitumor activity in vivo. 
Anti-SOX2 T cells may prevent myeloma
Arming antitumor T cells
T cells can kill tumors more effectively if a roadblock in their 
receptor signaling is removed, report Loeser et al. on page 879.
Most tumors are poor targets for the immune system as they 
frequently lack costimulatory molecules and present antigens 
that are only weakly immunogenic. The few tumor-specific 
T cells that do get generated are tolerized and fail to see the 
tumor as a dangerous enemy.
Strategies to induce strong antitumor T cell responses—
including cytokine treatment to coax tumors into expressing 
costimulatory proteins or vaccination with host dendritic cells 
loaded with tumor antigens—have not always worked. Loeser and 
colleagues decided instead to circumvent tolerogenic 
mechanisms within the antitumor T cells themselves.
Their target was the ubiquitin ligase cbl-b, which inhibits 
TCR signals by targeting downstream signaling proteins for 
proteasomal degradation. The group had previously shown that 
T cells lacking cbl-b are efficiently activated by weak antigens 
even in the absence of costimulation, suggesting that cbl-b 
functioned as an internal tolerance enforcer.
They now find that these T cells are efficient tumor killers 
as well. Mice lacking cbl-b were able to spontaneously reject 
tumors that were either injected into the animals or induced 
by UV exposure. Cbl-b–deficient CD8+ T cells destroyed tumors 
when transferred into wild-type animals. These cells developed 
into memory cells and offered long-lasting protection against 
tumor recurrence.
One pitfall of removing a tolerogenic T cell protein such as 
cbl-b is the threat of autoimmunity. The cbl-b–deficient mice 
do show signs of autoimmune damage. However, these side 
effects are not lethal, and the mice have a normal lifespan. 
The team now plans to test whether antitumor T cell activity 
in mice can be mediated by RNAi knock-down of cbl-b, as this 
strategy may be practical in humans. 
Mice that lack cbl-b spontaneously reject UV-induced tumors.
Patients who have anti-SOX2 T cells (solid 
line) are less likely to develop multiple 
myeloma than those lacking these 
T cells (dashed line).